325 related articles for article (PubMed ID: 2845409)
21. Mechanisms of DNA topoisomerase I-induced cell killing in the yeast Saccharomyces cerevisiae.
Fiorani P; Bjornsti MA
Ann N Y Acad Sci; 2000; 922():65-75. PubMed ID: 11193926
[TBL] [Abstract][Full Text] [Related]
22. Role for nucleolin/Nsr1 in the cellular localization of topoisomerase I.
Edwards TK; Saleem A; Shaman JA; Dennis T; Gerigk C; Oliveros E; Gartenberg MR; Rubin EH
J Biol Chem; 2000 Nov; 275(46):36181-8. PubMed ID: 10967121
[TBL] [Abstract][Full Text] [Related]
23. Increased camptothecin toxicity induced in mammalian cells expressing Saccharomyces cerevisiae DNA topoisomerase I.
Hann C; Evans DL; Fertala J; Benedetti P; Bjornsti MA; Hall DJ
J Biol Chem; 1998 Apr; 273(14):8425-33. PubMed ID: 9525954
[TBL] [Abstract][Full Text] [Related]
24. Evidence that mAMSA induces topoisomerase action.
Marshall B; Darkin S; Ralph RK
FEBS Lett; 1983 Sep; 161(1):75-8. PubMed ID: 6309576
[TBL] [Abstract][Full Text] [Related]
25. A specific transcriptional response of yeast cells to camptothecin dependent on the Swi4 and Mbp1 factors.
Lotito L; Russo A; Bueno S; Chillemi G; Fogli MV; Capranico G
Eur J Pharmacol; 2009 Jan; 603(1-3):29-36. PubMed ID: 19094980
[TBL] [Abstract][Full Text] [Related]
26. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II.
Rowe TC; Chen GL; Hsiang YH; Liu LF
Cancer Res; 1986 Apr; 46(4 Pt 2):2021-6. PubMed ID: 3004716
[TBL] [Abstract][Full Text] [Related]
27. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
28. SCT1 mutants suppress the camptothecin sensitivity of yeast cells expressing wild-type DNA topoisomerase I.
Kauh EA; Bjornsti MA
Proc Natl Acad Sci U S A; 1995 Jul; 92(14):6299-303. PubMed ID: 7603986
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide.
Nelson EM; Tewey KM; Liu LF
Proc Natl Acad Sci U S A; 1984 Mar; 81(5):1361-5. PubMed ID: 6324188
[TBL] [Abstract][Full Text] [Related]
30. A novel approach for organelle-specific DNA damage targeting reveals different susceptibility of mitochondrial DNA to the anticancer drugs camptothecin and topotecan.
de la Loza MC; Wellinger RE
Nucleic Acids Res; 2009 Mar; 37(4):e26. PubMed ID: 19151088
[TBL] [Abstract][Full Text] [Related]
31. Directed evolution to increase camptothecin sensitivity of human DNA topoisomerase I.
Scaldaferro S; Tinelli S; Borgnetto ME; Azzini A; Capranico G
Chem Biol; 2001 Sep; 8(9):871-81. PubMed ID: 11564555
[TBL] [Abstract][Full Text] [Related]
32. Enhanced CPT sensitivity of yeast cells and selective relaxation of Ga14 motif-containing DNA by novel Gal4-topoisomerase I fusion proteins.
Alessandri M; Beretta GL; Ferretti E; Mancia A; Khobta A; Capranico G
J Mol Biol; 2004 Mar; 337(2):295-305. PubMed ID: 15003448
[TBL] [Abstract][Full Text] [Related]
33. Role for topoisomerases in the release of DNA into the detergent-soluble fraction of eukaryotic cells.
Zhang LH; Mui SC; Todt JC; Strauss PR
Proc Natl Acad Sci U S A; 1986 Aug; 83(16):5871-4. PubMed ID: 3016725
[TBL] [Abstract][Full Text] [Related]
34. Multiple endonucleases function to repair covalent topoisomerase I complexes in Saccharomyces cerevisiae.
Deng C; Brown JA; You D; Brown JM
Genetics; 2005 Jun; 170(2):591-600. PubMed ID: 15834151
[TBL] [Abstract][Full Text] [Related]
35. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine.
Benedetti P; Fiorani P; Capuani L; Wang JC
Cancer Res; 1993 Sep; 53(18):4343-8. PubMed ID: 8395982
[TBL] [Abstract][Full Text] [Related]
36. Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: role of topoisomerase I.
Sørensen BS; Jensen PB; Sehested M; Jensen PS; Kjeldsen E; Nielsen OF; Alsner J
Biochem Pharmacol; 1994 Jun; 47(11):2105-10. PubMed ID: 8010996
[TBL] [Abstract][Full Text] [Related]
37. Reduced DNA break formation and cytotoxicity of the topoisomerase II drug 4'-(9'-acridinylamino)methanesulfon-m-anisidide when combined with hyperthermia in human and rodent cell lines.
Kampinga HH; van den Kruk G; Konings AW
Cancer Res; 1989 Apr; 49(7):1712-7. PubMed ID: 2538233
[TBL] [Abstract][Full Text] [Related]
38. Yeast systems for demonstrating the targets of anti-topoisomerase II agents.
Nitiss JL; Nitiss KC
Methods Mol Biol; 2001; 95():315-27. PubMed ID: 11089243
[No Abstract] [Full Text] [Related]
39. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I.
Covey JM; Jaxel C; Kohn KW; Pommier Y
Cancer Res; 1989 Sep; 49(18):5016-22. PubMed ID: 2548707
[TBL] [Abstract][Full Text] [Related]
40. Substitutions of Asn-726 in the active site of yeast DNA topoisomerase I define novel mechanisms of stabilizing the covalent enzyme-DNA intermediate.
Fertala J; Vance JR; Pourquier P; Pommier Y; Bjornsti MA
J Biol Chem; 2000 May; 275(20):15246-53. PubMed ID: 10809761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
